Infliximab for the treatment of rheumatoid arthritis. - Wikidata - awgldk - TriplyDB

Infliximab for the treatment of rheumatoid arthritis.

Infliximab for the treatment of rheumatoid arthritis.

http://www.wikidata.org/entity/Q34758388

about

Subcutaneous or intramuscular methotrexate for rheumatoid arthritis Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity Certolizumab pegol (CDP870) for rheumatoid arthritis in adults Down titration and discontinuation strategies of tumor necrosis factor blocking agents for rheumatoid arthritis in patients with low disease activity Erythropoiesis-stimulating agents for anemia in rheumatoid arthritis Interventions for periodontal disease in people with rheumatoid arthritis Ofatumumab for rheumatoid arthritis Tocilizumab for rheumatoid arthritis Adverse effects of biologics: a network meta-analysis and Cochrane overview TNF-alpha inhibitors for juvenile idiopathic arthritis Non-biologic pharmaceutical interventions for fatigue in rheumatoid arthritis Adverse effects of biologics: a network meta-analysis and Cochrane overview Certolizumab pegol (CDP870) for rheumatoid arthritis in adults Tocilizumab for rheumatoid arthritis Biologics for rheumatoid arthritis: an overview of Cochrane reviews Golimumab for rheumatoid arthritis TNF-alpha inhibitors for psoriatic arthritis Biologic interventions for fatigue in rheumatoid arthritis Anakinra for rheumatoid arthritis Abatacept for rheumatoid arthritis Biologic interventions for fatigue in rheumatoid arthritis Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis.The impact of patient-perceived restricted access to anti-TNF therapy for rheumatoid arthritis: a qualitative study.The relationship between change in subjective outcome and change in disease: a potential paradox Systematic review and network meta-analysis of combination and monotherapy treatments in disease-modifying antirheumatic drug-experienced patients with rheumatoid arthritis: analysis of American College of Rheumatology criteria scores 20, 50, and 70 Tumour necrosis factor alpha blocking agents in refractory adult Still's disease: an observational study of 20 cases.Association between anti-TNF therapy for rheumatoid arthritis and hypertension: a meta-analysis of randomized controlled trials.RR interval variability is inversely related to inflammatory markers: the CARDIA study The Budget Impact of Biosimilar Infliximab (Remsima®) for the Treatment of Autoimmune Diseases in Five European Countries Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA).Olfactory ecto-mesenchymal stem cells possess immunoregulatory function and suppress autoimmune arthritis.A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview.Efficacy and safety of infliximab-biosimilar compared to other biological drugs in rheumatoid arthritis: a mixed treatment comparison.Infliximab, methotrexate and their combination for the treatment of rheumatoid arthritis: a systematic review and meta-analysis.The Comparative Safety of TNF Inhibitors in Ankylosing Spondylitis-a Meta-Analysis Update of 14 Randomized Controlled Trials.Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.

P2860

Q24187565-98C7F304-863E-460A-81D4-7F4B65B70290 Q24193435-38E02C4C-F1F8-4C44-840D-24EC338D38D3 Q24193535-69081A33-83CC-4094-A1B6-CA7E160E547C Q24198056-422C90FF-2EB9-4DE8-BE01-40929EF668CF Q24200775-49B13E52-5798-4631-AB7B-1D8B466DB226 Q24200961-438790BF-7717-4163-9875-217ED3ECFDC7 Q24202719-30C471A1-D6FC-4014-94C6-CB8DBE4B37F2 Q24234126-BDE2A53D-EF25-4B14-8514-82342A821B0B Q24234197-C3AA2D9B-A28B-48A5-8ACF-BDEEF3668399 Q24234429-2EBFC1F0-FC85-4E91-82D1-6EFE502AF3C4 Q24234928-C6BB3F69-A418-477E-B423-8C6DA57630D4 Q24235218-6C2AFA64-FEC8-4657-BC3E-807588EE8039 Q24236701-3C00C135-5E36-4677-A3FF-F83BCB402DF4 Q24239949-78174714-D602-42A5-A14C-B00C7BA02723 Q24240731-45048A3B-2EFF-4294-9192-CEAC80BE6F9D Q24240895-64A4F12D-3CB9-4FF5-B1B8-C7B747C2D364 Q24240905-269CDF22-259F-4E38-91AF-CE6FC0F8949D Q24241246-E2B61487-0BBA-40E2-BF63-53FB22D8CD1F Q24241707-EA202C48-2344-4E67-9A60-93CDB40E3E36 Q24242770-364F0131-2292-4117-AA63-2EFD6E43B6B0 Q26471538-100031F5-28F6-471E-B900-465DE214B35F Q30235341-7AF63DB0-5005-4F4A-9BF5-349F1F67F157 Q33918359-CEBB6E7F-9648-4BE3-894E-01041B065853 Q34073425-447B2A78-8A77-47D8-8D6B-A1BB800E0964 Q34523450-32848988-F850-45BE-8591-C40DB40D29BD Q35555229-3EDB41CE-8D49-4930-82CD-85297EBEA791 Q35599025-DC182D34-B572-4D0F-9E34-8CD8F6D2AC3C Q35844062-F75C114F-E4DB-4DF2-91F3-A7BD872C6BA9 Q36059239-06081536-4146-4947-8F98-4A8963B4287B Q36195284-6FCE6F9D-3D2A-47B6-A340-95E6AB5A75A4 Q36870064-EDA22729-5B9E-4155-9928-787554E623E0 Q37428436-ACDD1671-0287-4BE4-8293-C9BF89184EC9 Q38212142-443A459A-2F88-4F3B-A974-7E1421F3614E Q38320157-ACAB4CFA-57EA-4DAD-9EDD-C27CB296D63B Q38674463-74B1EA4A-F672-4132-AE21-20F0F7DCD36D Q47836056-773574A9-4991-4B70-B84F-92FF94A59B5C

P2860

Infliximab for the treatment of rheumatoid arthritis.

http://www.wikidata.org/entity/Q34758388

description

2002 nî lūn-bûn

@nan

2002 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年学术文章

@wuu

2002年学术文章

@zh-cn

2002年学术文章

@zh-hans

2002年学术文章

@zh-my

2002年学术文章

@zh-sg

2002年學術文章

@yue

name

Infliximab for the treatment of rheumatoid arthritis.

@ast

Infliximab for the treatment of rheumatoid arthritis.

@en

Infliximab for the treatment of rheumatoid arthritis.

@nl

type

label

Infliximab for the treatment of rheumatoid arthritis.

@ast

Infliximab for the treatment of rheumatoid arthritis.

@en

Infliximab for the treatment of rheumatoid arthritis.

@nl

prefLabel

Infliximab for the treatment of rheumatoid arthritis.

@ast

Infliximab for the treatment of rheumatoid arthritis.

@en

Infliximab for the treatment of rheumatoid arthritis.

@nl

P1433

Q34758388-8EE390D0-C7FB-4128-9876-F74C302B0BBB

P1476

Q34758388-1A2143C4-0F02-4FF6-AD12-25F93A88FC42

P2093

Q34758388-34C003DE-5C27-4B2B-9D25-EDC4F4F64C38

Q34758388-59214A6B-AF81-411E-976B-27145218E06B

Q34758388-9C821BC7-6B7A-4D13-8F8E-4FAB2051EAD5

Q34758388-A7FC657C-EB9E-48F2-8E1D-C82CF30DE9D4

Q34758388-C9F09E53-2BE0-4475-B322-8513B1DB1EF2

Q34758388-F76982D3-640B-4369-993B-92FE8D20D776

P2860

Q34758388-076182EF-93AE-4307-B9CA-12D9117BB935

Q34758388-0F7A2009-029B-44E3-8A51-15FE9875C784

Q34758388-2796C216-0011-4E64-8161-B34A633737EE

Q34758388-437869FB-9107-4112-B42D-7B179804D786

Q34758388-6CCE7818-D702-4B7D-9E7D-EA2F88DAD896

Q34758388-8884D378-A95E-4972-B86A-83E870626E42

Q34758388-C7A25D31-0906-4111-80A4-0C7E6AF90672

Q34758388-C866E0D9-D65F-453C-B710-ECECDE457952

Q34758388-D3845ECE-3312-4ADC-B9F1-BFAE3D57E339

Q34758388-EA849B31-59D9-4081-BB95-7D130B08994E

P304

Q34758388-739480F7-FB5F-4C72-905A-B62BF831CA25

P31

Q34758388-A12DC7DC-FD48-4864-B0CA-862F0ECFA03E

P356

Q34758388-065B6208-8EA4-4055-BCD5-791512772EBD

P433

Q34758388-41F8A947-1BD4-4E97-AA58-F8CFD0E18B00

P50

Q34758388-97DA712B-6878-4BAA-A9AD-EC78365EBACA

P577

Q34758388-662ADDAA-418C-4336-A45A-D65A60DD23B8

P698

Q34758388-CAF179AE-72E8-4AC6-B3FE-679190481875

P356

14651858.CD003785

P1433

Cochrane Database of Systematic Reviews

P1476

Infliximab for the treatment of rheumatoid arthritis.

@en

P2093

A Burls

http://www.w3.org/2001/XMLSchema#string

A Cranney

http://www.w3.org/2001/XMLSchema#string

B Blumenauer

http://www.w3.org/2001/XMLSchema#string

G Wells

http://www.w3.org/2001/XMLSchema#string

M Hochberg

http://www.w3.org/2001/XMLSchema#string

M Judd

http://www.w3.org/2001/XMLSchema#string

P2860

The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.

Suppression of fever and the acute-phase response in a patient with juvenile chronic arthritis treated with monoclonal antibody to tumour necrosis factor-alpha (cA2).

The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials.

Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis.

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis.

P304

CD003785

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/14651858.CD003785

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P50

P577

2002-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12137712

http://www.w3.org/2001/XMLSchema#string